- Home
- SOHO vs MBRX Comparison
SOHO vs MBRX Comparison
Compare SOHO & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOHO
- MBRX
- Stock Information
- Founded
- SOHO 2004
- MBRX 2015
- Country
- SOHO United States
- MBRX United States
- Employees
- SOHO N/A
- MBRX N/A
- Industry
- SOHO Real Estate Investment Trusts
- MBRX Biotechnology: Pharmaceutical Preparations
- Sector
- SOHO Real Estate
- MBRX Health Care
- Exchange
- SOHO Nasdaq
- MBRX Nasdaq
- Market Cap
- SOHO 15.4M
- MBRX 12.9M
- IPO Year
- SOHO 2004
- MBRX 2016
- Fundamental
- Price
- SOHO $0.89
- MBRX $0.34
- Analyst Decision
- SOHO Hold
- MBRX Strong Buy
- Analyst Count
- SOHO 1
- MBRX 3
- Target Price
- SOHO $1.50
- MBRX $5.33
- AVG Volume (30 Days)
- SOHO 43.6K
- MBRX 5.1M
- Earning Date
- SOHO 08-12-2025
- MBRX 08-13-2025
- Dividend Yield
- SOHO N/A
- MBRX N/A
- EPS Growth
- SOHO N/A
- MBRX N/A
- EPS
- SOHO N/A
- MBRX N/A
- Revenue
- SOHO $182,158,199.00
- MBRX N/A
- Revenue This Year
- SOHO $13.93
- MBRX N/A
- Revenue Next Year
- SOHO N/A
- MBRX N/A
- P/E Ratio
- SOHO N/A
- MBRX N/A
- Revenue Growth
- SOHO 3.11
- MBRX N/A
- 52 Week Low
- SOHO $0.59
- MBRX $0.25
- 52 Week High
- SOHO $1.54
- MBRX $4.71
- Technical
- Relative Strength Index (RSI)
- SOHO 51.14
- MBRX 30.62
- Support Level
- SOHO $0.94
- MBRX $0.29
- Resistance Level
- SOHO $1.04
- MBRX $0.36
- Average True Range (ATR)
- SOHO 0.08
- MBRX 0.05
- MACD
- SOHO -0.01
- MBRX 0.00
- Stochastic Oscillator
- SOHO 34.58
- MBRX 21.55
About SOHO Sotherly Hotels Inc.
Sotherly Hotels Inc is engaged in Hotel operations. The company is a self-managed and self-administered lodging real estate investment trust that was formed to own, acquire, renovate, and reposition full-service, upscale, and upper-upscale hotel properties located in primary markets in the mid-Atlantic and southern United States. It generates revenue through the rooms, food, beverage, and other services. Geographically, the group has its presence in the regions of Florida, Georgia, Indiana, Maryland, North Carolina, Pennsylvania, Texas, and Virginia.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.